Plasma and Tissue Specific miRNA Expression Pattern and Functional Analysis Associated to Colorectal Cancer Patients

被引:43
作者
Cojocneanu, Roxana [1 ]
Braicu, Cornelia [1 ]
Raduly, Lajos [1 ]
Jurj, Ancuta [1 ]
Zanoaga, Oana [1 ]
Magdo, Lorand [1 ]
Irimie, Alexandru [2 ,3 ]
Muresan, Mihai-Stefan [4 ,5 ]
Ionescu, Calin [4 ,5 ]
Grigorescu, Mircea [6 ]
Berindan-Neagoe, Ioana [1 ,7 ,8 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom & Translat Med, 23 Marinescu St, Cluj Napoca 400015, Romania
[2] Oncol Inst Prof Dr Ion Chiricuta, Dept Surg, Cluj Napoca 400015, Romania
[3] Univ Med & Pharm Iuliu Hatieganu, Dept Surg Oncol & Gynecol Oncol, Cluj Napoca 400015, Romania
[4] Municipal Hosp, Surg Dept 5, Cluj Napoca 400139, Romania
[5] Iuliu Hatieganu Univ Med & Pharm, Dept Surg, 23 Marinescu St, Cluj Napoca 400015, Romania
[6] Iuliu Hatieganu Univ Med & Pharm, Med Clin 3, Gastroenterol & Hepatol Dept, Cluj Napoca 400162, Romania
[7] Univ Med & Pharm Iuliu Hatieganu, MEDFUTURE Res Ctr Adv Med, 23 Marinescu St, Cluj Napoca 400015, Romania
[8] Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom & Expt Pathol, Republ 34 St, Cluj Napoca 400015, Romania
基金
欧盟地平线“2020”;
关键词
colorectal cancer; plasma; microarray; miRNA; biomarker; CARCINOMA; DICER; AGO2; CELL; APOPTOSIS; 5-FLUOROURACIL; IDENTIFICATION; RESISTANCE; MICRORNAS; THERAPY;
D O I
10.3390/cancers12040843
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An increasing number of studies suggest the implication of microRNAs (miRNAs) in colorectal (CRC) carcinogenesis and disease progression. Nevertheless, the basic mechanism is not yet clear. We determined plasma miRNA expression levels using Agilent microarray technology followed by overlapping with The Cancer Genome Atlas (TCGA) tissue data and a qRT-PCR validation step and analysis of the altered miRNA signatures to emphasize new mechanistic insights. For TGCA dataset, we identified 156 altered miRNAs (79 downregulated and 77 upregulated) in colorectal tissue samples versus normal tissue. The microarray experiment is based on 16 control samples, 38 CRC plasma samples from colorectal cancer patients who have not undergone chemotherapy, and 17 chemo-treated samples. In the case of the analysis of CRC cancer versus healthy control we identified 359 altered miRNAs (214 downregulated and 60 upregulated), considering as the cutoff value a fold-change of +/- 1.5 and p < 0.01. An additional microarray analysis was performed on plasma from untreated colorectal cancer (n = 38) and chemotherapy-treated colorectal cancer patients (n = 17), which revealed 15 downregulated miRNAs and 53 upregulated miRNAs, demonstrating that the plasma miRNA pattern is affected by chemotherapy and emphasizing important regulators of drug resistance mechanisms. For the validation of the microarray data, we selected a panel of 4 miRNAs from the common miRNA signatures for colon and rectal cancer (miR-642b-3p, miR-195-5p and miR-4741). At the tissue level, the expression levels were in agreement with those observed in colorectal plasma. miR-1228-3p, the top upregulated miRNA in CRC, was chosen to be validated on tissue and plasma samples, as it was demonstrated to be downregulated at tissue level in our patient cohort. This was confirmed by TCGA data and was one example of ta ranscript that has a different expression level between tumor tissue and plasma. Developing more efficient investigation methods will help explain the mechanisms responsible for miRNAs released in biofluids, which is the most upregulated transcript in colorectal plasma samples and which can function as a prediction tool within the oncological field.
引用
收藏
页数:21
相关论文
共 44 条
[1]   A Systems Biology Approach Identifies SART1 as a Novel Determinant of Both 5-Fluorouracil and SN38 Drug Resistance in Colorectal Cancer [J].
Allen, Wendy L. ;
Stevenson, Leanne ;
Coyle, Vicky M. ;
Jithesh, Puthen V. ;
Proutski, Irina ;
Carson, Gail ;
Gordon, Michael A. ;
Lenz, Heinz-Josef D. ;
Van Schaeybroeck, Sandra ;
Longley, Daniel B. ;
Johnston, Patrick G. .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (01) :119-131
[2]  
Berindan-Neagoe I, 2013, J GASTROINTEST LIVER, V22, P37
[3]   Down-regulation of Dicer and Ago2 is associated with cell proliferation and apoptosis in prostate cancer [J].
Bian, Xiao-Jie ;
Zhang, Gui-Ming ;
Gu, Cheng-Yuan ;
Cai, Ying ;
Wang, Chao-Fu ;
Shen, Yi-Jun ;
Zhu, Yao ;
Zhang, Hai-Liang ;
Dai, Bo ;
Ye, Ding-Wei .
TUMOR BIOLOGY, 2014, 35 (11) :11571-11578
[4]  
Bochis OV, 2015, J GASTROINTEST LIVER, V24, P225, DOI 10.15403/jgld.2014.1121.242.skp2
[5]  
Braicu C, 2013, CHIRURGIA-BUCHAREST, V108, P849
[6]   Connecting the dots between different networks: miRNAs associated with bladder cancer risk and progression [J].
Braicu, Cornelia ;
Buiga, Rares ;
Cojocneanu, Roxana ;
Buse, Mihail ;
Raduly, Lajos ;
Pop, Laura Ancuta ;
Chira, Sergiu ;
Budisan, Liviuta ;
Jurj, Ancuta ;
Ciocan, Cristina ;
Magdo, Lorand ;
Irimie, Alexandru ;
Dobrota, Florentin ;
Petrut, Bogdan ;
Berindan-Neagoe, Ioana .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
[7]   Comprehensive analysis of circular RNAs in pathological states: biogenesis, cellular regulation, and therapeutic relevance [J].
Braicu, Cornelia ;
Zimta, Andreea-Alina ;
Gulei, Diana ;
Olariu, Andrei ;
Berindan-Neagoe, Ioana .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2019, 76 (08) :1559-1577
[8]   Aberrant miRNAs expressed in HER-2 negative breast cancers patient [J].
Braicu, Cornelia ;
Raduly, Lajos ;
Morar-Bolba, Gabriela ;
Cojocneanu, Roxana ;
Jurj, Ancuta ;
Pop, Laura-Ancuta ;
Pileczki, Valentina ;
Ciocan, Cristina ;
Moldovan, Alin ;
Irimie, Alexandru ;
Eniu, Alexandru ;
Achimas-Cadariu, Patriciu ;
Paradiso, Angelo ;
Berindan-Neagoe, Ioana .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
[9]   NCRNA Combined Therapy as Future Treatment Option for Cancer [J].
Braicu, Cornelia ;
Catana, Cristina ;
Calin, George A. ;
Berindan-Neagoe, Ioana .
CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (42) :6565-6574
[10]  
Braicu C, 2013, CURR MED CHEM, V20, P3561